Vancouver, British Columbia-based AbCellera closed a Series B financing worth $105 million, led by OrbiMed and DCVC Bio.
Two years after Boston-based HotSpot Therapeutics launched, the company secured $65 million in Series B funding to advance the development of allosteric therapies that target “regulatory hotspots” in the body into the clinic.
Cambridge, Mass.-based Affinivax completed a $120 million Series B financing round that will be used to advance the company’s vaccine and immunotherapy candidates.
Waltham, Massachusetts-based TScan Therapeutics entered a collaboration agreement with Novartis to discover and develop novel T-cell Receptor (TCR)-engineered T-cell therapies for solid tumors.
Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance lead therapeutic candidates into clinical studies.
Redwood City, California-based Karius closed on a $165 million Series B round.
Business updates for various pharma and life science companies around the globe.
San Francisco-based Spruce Biosciences closed on a Series B financing round valued at $88 million, as the company develops tildacerfont for the rare genetic disorder congenital adrenal hyperplasia (CAH).
Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.
Less than one month after filing for bankruptcy, uBiome is shutting the Bay Area microbiome company’s doors and selling off assets.